<DOC>
	<DOCNO>NCT01230385</DOCNO>
	<brief_summary>Randomized , open-label , parallel group study group 75 healthy subject , evaluate safety toleration 2 different dos lersivirine administer either feed fast ( propose Phase 3 formulation ) give 21 day , compare lersivirine 500 mg QD ( Phase 2b formulation ) . The pharmacokinetics lersivirine group also evaluate .</brief_summary>
	<brief_title>Safety And Tolerability Of Multiple Dose Lersivirine For 21 Days In Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subject . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Use tobacco nicotinecontaining product excess equivalent 5 cigarette per day . Use prescription nonprescription drug dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose study medication . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>lersivirine</keyword>
	<keyword>UK-453</keyword>
	<keyword>061</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>HIV</keyword>
	<keyword>non-nucleoside reverse transcriptase inhibitor</keyword>
	<keyword>NNRTI</keyword>
</DOC>